New vaccine aims to shield african infants from two deadly infections
NCT ID NCT07286370
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new vaccine called iNTS-TCV in 537 infants in Africa. The vaccine is designed to protect against two serious bacterial infections: invasive nontyphoidal salmonella (iNTS) and typhoid fever. Researchers are giving the vaccine to infants starting at either 6 weeks or 6 months old to check its safety and how well it triggers an immune response. The goal is to find the best dose and schedule for future use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- iNTS-TCV vaccine (combined vaccine against invasive nontyphoidal salmonella and typhoid fever)
- What this could lead to
- If successful, this vaccine could help protect infants in Africa from two serious bacterial infections—nontyphoidal salmonella and typhoid fever—potentially saving many lives.
- What could go wrong
- This is an early phase 2a trial with only 537 infants, so it is still testing safety and the right dose. The vaccine may not produce strong enough immunity or could have side effects. Results may not apply to all regions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE NONTYPHOIDAL SALMONELLA DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
RECRUITINGBanjul, The Gambia
More trials for these conditions
Other studies related to the condition(s) this trial covers.